Three-Year Follow-Up of Dose-Dense Mini-CVD in Combination With Inotuzumab Ozogamicin and Blinatumomab for Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-866; Location: LEVEL 3, HALL B3; "Cycles 2, 4, and 6 were mini-methotrexate and ara-C, InO 0.3 mg/m2 day 2 and 0.3 mg/m2 day 8 (of cycles 2 and 4), blina 28 mg days 4–21, with peg-G-CSF. Patients received 12 intrathecal chemotherapies, rituximab if CD20+, and ursodiol... In R/R B-ALL, dose-dense mini-CVD with InO and blina leads to 100% response rates, 95% NGSMRDnegativity, and 3-year EFS and OS rates of 69% and 79%, respectively. Proceeding with CAR-T therapy consolidation leads to favorable outcomes, with a 3-year EFS rate >80%. ara-C: cytarabine, ASCT: allogeneic stem cell transplantation, B-ALL: B-cell acute lymphoblastic leukemia, BCR::ABL1: breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1, CAR-T: chimeric antigen receptor T-cell, CD: cluster of differentiation, CR: complete remission, CRi: complete remission with incomplete count recovery, CVD: cyclophosphamide, vincristine, dexamethasone, EFS: event-free survival, FC: flow cytometry, MRD: measurable residual..."
Clinical • Combination therapy • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • CD20
|
|
Hannah Goulart MD; Hagop Kantarjian MD; Nitin Jain MD; Farhad Ravandi MD; Tapan M Kadia MD; Courtney DiNardo MD; Naval Daver MD; Naveen Pemmaraju MD; Alex Bataller MD; Fadi Haddad MD; Jayastu Senapati MBBS; Rebecca Garris MD; Guillermo Garcia-Manero MD; Nicholas J Short MD; Elias Jabbour MD
|